Regenerative medicine specialist Tissue Regenix PLC (LON:TRX) has confirmed talks to buy US rival Cellright.
In a brief statement, the Leeds-based group said a temporary restraining order had been applied for by one of Cellright Technologies LLC’s members against the sale to Tissue.
Following the application Tissue Regenix confirmed discussions were underwa though it said there was no certainty yet that the acquisition will go ahead.
No other details were released.
Texas-based Cellright make a range of regenerative and graft products, notably Matrix 01 a human bone cell scaffold that is processed using the US company’s BioRinse technology.
Tissue Regenix supplies skin, cartilages, ligaments and valves for grafts from both animals and human tissue banks that have been washed and the acellular scaffold kept intact.